Pegaspargase: A Review in Acute Lymphoblastic Leukaemia

AbstractPegaspargase (Oncaspar®), a pegylated form of nativeEscherichia coli-derivedl-asparaginase (hereafter referred asE. colil-asparaginase), is indicated in the USA and EU for the treatment of acute lymphoblastic leukaemia (ALL) as a component of multi-agent chemotherapy in paediatric and adult patients. Relative toE. colil-asparaginase, pegaspargase has a prolonged circulation time, thereby offering less frequent administration. Moreover, pegylation ofE. colil-asparaginase may diminish the immunogenicity of the enzyme. Based on extensive evidence, intramuscular (IM) or intravenous (IV) administration of pegaspargase as a component of a multi-agent chemotherapy is an effective first-line treatment for paediatric and adult patients with ALL, as well as for the treatment of paediatric and adult patients with ALL and hypersensitivity toE. colil-asparaginase. Pegaspargase had a manageable tolerability profile in paediatric and adult patients with newly diagnosed ALL, with the most commonly occurring adverse events being generally consistent to that seen withE. colil-asparaginase. Pegaspargase treatment in patients with relapsed ALL and hypersensitivity toE. colil-asparaginase had a similar tolerability profile to that observed in patients with newly diagnosed ALL. Given the potentially reduced immunogenicity and more convenient dosage regimen overE. colil-asparaginase, pegaspargase remains an important and effective treatment option for paediatric and adult patients with ALL...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research